Advertisement





Click here for more guidelines.
CME Topic Collections Past Issues Search Current Issue Home
     

J Am Coll Cardiol, 2001; 38:1130-1136
© 2001 by the American College of Cardiology Foundation
This Article
Right arrow Figures Only
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Wiedemann, R.
Right arrow Articles by Olschewski, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Wiedemann, R.
Right arrow Articles by Olschewski, H.

CLINICAL STUDY

Atrial natriuretic peptide in severe primary and nonprimary pulmonary hypertension

Response to iloprost inhalation

Ralph Wiedemann, MDa, H. Ardeschir Ghofrani, MDa, Norbert Weissmann, PhDa, Ralph Schermuly, PhDa, Karin Quanz, MDa, Friedrich Grimminger, MD, PhDa, Werner Seeger, MDa and Horst Olschewski, MD, FESCa

a Department of Internal Medicine II, Justus-Liebig-University, Giessen, Germany

Manuscript received December 15, 2000; revised manuscript received May 31, 2001, accepted June 19, 2001.

Reprint requests and correspondence: Dr. Horst Olschewski, Department of Internal Medicine II, Klinikstr. 36, 35392 Giessen, Germany
horst.olschewski{at}innere.med.uni-giessen.de

OBJECTIVES

The goal of this study was to assess atrial natriuretic peptide (ANP) levels during inhalation of iloprost in severe primary (PPH) and nonprimary pulmonary hypertension (NPPH).

BACKGROUND

The ANP system is activated in pulmonary hypertension and may help protect from right ventricular (RV) decompensation. It is unknown if ANP regulation is the same in severe PPH and NPPH and if the dynamic regulation is intact in a highly activated ANP system.

METHODS

In 11 patients with PPH and seven patients with NPPH, right heart catheter investigations were performed. Pulmonary and systemic artery ANP and cyclic guanosine monophosphate (cGMP) levels as well as hemodynamics were measured before and after iloprost inhalation.

RESULTS

The baseline hemodynamics of patients with PPH and patients with NPPH were comparable (mean pulmonary artery pressure [mPAP]: 61 ± 5 mm Hg vs. 52 ± 5 mm Hg, pulmonary vascular resistance [PVR]: 1,504 ± 153 dyne·s·cm–5 vs. 1,219 ± 270 dyne·s·cm–5. Atrial natriuretic peptide and cGMP levels were increased about tenfold and fivefold compared with controls in both PPH and NPPH. Iloprost inhalation significantly decreased mPAP (–9.1 ± 2.5 mm Hg vs. –7.9 ± 1.5 mm Hg), PVR (–453 ± 103 dyne·s·cm–5 vs. –381 ± 114 dyne·s·cm–5), ANP (–99 ± 63 pg/ml vs. –108 ± 47 pg/ml) and cGMP (–4.6 ± 0.9 nM vs. –4.2 ± 1.6 nM). Baseline ANP including all patients significantly correlated with PVR, right atrial pressure, cardiac index, RV ejection fraction, mixed venous oxygen saturation and cGMP.

CONCLUSIONS

The ANP system is highly activated in patients with severe PPH and NPPH. Atrial natriuretic peptide levels are significantly correlated with parameters of RV function and pre- and afterload. Iloprost inhalation causes a rapid decrease in ANP and cGMP in parallel with pulmonary vasodilation and hemodynamic improvement.

Abbreviations and Acronyms
  ANP = atrial natriuretic peptide
  cGMP = cyclic guanosine monophosphate
  CI = cardiac index
  CO = cardiac output
  COPD = chronic obstructive pulmonary disease
  CT = computed tomography
  eNOS = endothelial nitric oxide synthase
  mPAP = mean pulmonary arterial pressure
  mSAP = mean systemic arterial pressure
  NPPH = nonprimary pulmonary hypertension
  PAWP = pulmonary artery wedge pressure
  PPH = primary pulmonary hypertension
  PVR = pulmonary vascular resistance
  RAP = right atrial pressure
  RIA = radioimmunoassay
  RV = right ventricle, right ventricular
  RVEF = right ventricular ejection fraction
  SvO2 = mixed venous oxygen saturation




This article has been cited by other articles:


Home page
Eur Respir JHome page
G. Warwick, P. S. Thomas, and D. H. Yates
Biomarkers in pulmonary hypertension
Eur. Respir. J., August 1, 2008; 32(2): 503 - 512.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
J. Behr and J. H. Ryu
Pulmonary hypertension in interstitial lung disease
Eur. Respir. J., June 1, 2008; 31(6): 1357 - 1367.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
H. H. Leuchte, M. El Nounou, J. C. Tuerpe, B. Hartmann, R. A. Baumgartner, M. Vogeser, O. Muehling, and J. Behr
N-terminal Pro-Brain Natriuretic Peptide and Renal Insufficiency as Predictors of Mortality in Pulmonary Hypertension
Chest, February 1, 2007; 131(2): 402 - 409.
[Abstract] [Full Text] [PDF]


Home page
Exp. Biol. Med.Home page
F. D. Wagner, S. Buz, H. Zais, J. P. Stasch, R. Hetzer, and B. Hocher
Humoral and hemodynamic responses after left ventricular assist device implantation and heart transplantation.
Experimental Biology and Medicine, June 1, 2006; 231(6): 861 - 864.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
H. H. Leuchte, R. A. Baumgartner, M. E. Nounou, M. Vogeser, C. Neurohr, M. Trautnitz, and J. Behr
Brain Natriuretic Peptide Is a Prognostic Parameter in Chronic Lung Disease
Am. J. Respir. Crit. Care Med., April 1, 2006; 173(7): 744 - 750.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
H. H. Leuchte, M. Holzapfel, R. A. Baumgartner, C. Neurohr, M. Vogeser, and J. Behr
Characterization of Brain Natriuretic Peptide in Long-term Follow-up of Pulmonary Arterial Hypertension
Chest, October 1, 2005; 128(4): 2368 - 2374.
[Abstract] [Full Text] [PDF]


Home page
The Annals of PharmacotherapyHome page
S. E Baker and R. H. Hockman
Inhaled Iloprost in Pulmonary Arterial Hypertension
Ann. Pharmacother., July 1, 2005; 39(7): 1265 - 1274.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
H. A. Ghofrani, R. Voswinckel, F. Reichenberger, H. Olschewski, P. Haredza, B. Karadas, R. T. Schermuly, N. Weissmann, W. Seeger, and F. Grimminger
Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: A randomized prospective study
J. Am. Coll. Cardiol., October 6, 2004; 44(7): 1488 - 1496.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
L. B. Yap, D. Mukerjee, P. M. Timms, H. Ashrafian, and J. G. Coghlan
Natriuretic Peptides, Respiratory Disease, and the Right Heart
Chest, October 1, 2004; 126(4): 1330 - 1336.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Respir. Crit. Care Med.Home page
H. H. Leuchte, C. Neurohr, R. Baumgartner, M. Holzapfel, W. Giehrl, M. Vogeser, and J. Behr
Brain Natriuretic Peptide and Exercise Capacity in Lung Fibrosis and Pulmonary Hypertension
Am. J. Respir. Crit. Care Med., August 15, 2004; 170(4): 360 - 365.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
A. Peacock, R. Naeije, N. Galie, and J.T. Reeves
End points in pulmonary arterial hypertension: the way forward
Eur. Respir. J., June 1, 2004; 23(6): 947 - 953.
[Abstract] [Full Text] [PDF]


Home page
J Am Coll CardiolHome page
H. H. Leuchte, M. Holzapfel, R. A. Baumgartner, I. Ding, C. Neurohr, M. Vogeser, T. Kolbe, M. Schwaiblmair, and J. Behr
Clinical significance of brain natriuretic peptide in primary pulmonary hypertension
J. Am. Coll. Cardiol., March 3, 2004; 43(5): 764 - 770.
[Abstract] [Full Text] [PDF]


Home page
Eur Respir JHome page
D. Chemla, V. Castelain, P. Herve, Y. Lecarpentier, and S. Brimioulle
Haemodynamic evaluation of pulmonary hypertension
Eur. Respir. J., November 1, 2002; 20(5): 1314 - 1331.
[Abstract] [Full Text] [PDF]



 
  CME Topic Collections Past Issues Search Current Issue Home

Advertisement